Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma-Reference-Cited by-同舟云学术

Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma

Published:2021-10-11 Issue:12 Volume:60 Page:1611-1620
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Bruno Karine de Aguiar¹,Sobreira da Silva Mario Jorge¹^ORCID,Chaves Gabriela Villaça¹

Affiliation:

1. Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2021.1983210

Reference76 articles.

1. World Health Organization – WHO. International Agency for Research on Cancer. GLOBOCAN 2020: Cancer Today – Estimated number of new cases in 2020, worldwide, female, all ages; 2020. [cited 2021 Jan 1]. Available from: https://gco.iarc.fr/today/

2. Brazil. Ministry of Health. National Cancer Institute José Alencar Gomes da Silva (INCA). Estimates 2020: Cancer Incidence in Brazil, Rio de Janeiro, 122. p. 2019. [cited 2021 Jan 1]. Available from: https://www.inca.gov.br/

3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD. 2020. [cited 2021 Jan 1]. Available from: https://seer.cancer.gov/csr/1975_2017//

4. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

5. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between body composition phenotypes and treatment toxicity in women with cervical cancer undergoing chemoradiotherapy;Nutrition;2024-11

2. Assessing Sarcopenia in Advanced‐Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Case Series;Cancer Reports;2024-08

3. Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy;The Oncologist;2024-07-09

4. Reply – Letter to the editor: Different computed tomography parameters for defining myosteatosis in patients with advanced non-small cell lung cancer;Clinical Nutrition ESPEN;2024-06

5. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity;Cancer Chemotherapy and Pharmacology;2024-05-11